Intercept to Present at Upcoming Investor Conferences
Get Alerts ICPT Hot Sheet
Join SI Premium – FREE
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
- Baird 2016 Global Healthcare Conference on September 8, 2016 at 2:35 p.m. Eastern Time
- Morgan Stanley Global Healthcare Conference on September 13, 2016 at 1:30 p.m. Eastern Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]Source: Intercept Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TNS is the Only Provider in Europe to Offer Full-Service, Vendor-Neutral Market Data Management Solutions for Financial Institutions
- Notice of Extraordinary General Meeting Adevinta Asa
- InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 25
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!